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Abstract: Investigations of magnetic micro- and nanoparticles for targeted drug delivery began 
over 30 years ago. Since that time, major progress has been made in particle design and synthesis 
techniques, however, very few clinical trials have taken place. Here we review advances in 
magnetic nanoparticle design, in vitro and animal experiments with magnetic nanoparticle-based 
drug and gene delivery, and clinical trials of drug targeting.
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Introduction
The concept of using magnetic micro- and nanoparticles for drug delivery was proposed 
in the late 1970s by Widder, Senyi and colleagues (Senyi et al 1978; Widder et al 1978). 
The basic premise is that therapeutic agents are attached to, or encapsulated within, a 
magnetic micro- or nanoparticle. These particles may have magnetic cores with a poly-
mer or metal coating which can be functionalized, or may consist of porous polymers 
that contain magnetic nanoparticles precipitated within the pores. By functionalizing 
the polymer or metal coating it is possible to attach, for example, cytotoxic drugs for 
targeted chemotherapy or therapeutic DNA to correct a genetic defect.
Once attached, the particle/therapeutic agent complex is injected into the blood-
stream, often using a catheter to position the injection site near the target. Magnetic 
ﬁ  elds, generally from high-ﬁ  eld, high-gradient, rare earth magnets are focused over 
the target site and the forces on the particles as they enter the ﬁ  eld allow them to be 
captured and extravasated at the target. While this may be effective for targets close to 
the body’s surface, as the magnetic ﬁ  eld strength falls off rapidly with distance, sites 
deeper within the body become more difﬁ  cult to target. Some groups have recently 
proposed a way around this problem by implanting magnets near the target site, within 
the body (Kubo et al 2000; Yellen et al 2005).
Magnetic nanoparticle techniques can also be used for in vitro gene transfec-
tion. In this case, a high-ﬁ  eld, high-gradient is positioned under the multi-well plate, 
culture ﬂ  ask or petri dish in which the cells are growing. DNA is attached to magnetic 
nanoparticles (the details of this process follow later in this review) and the magnet 
increases sedimentation rates, particle internalization and gene expression. Internal-
ization normally occurs through a process of endocytosis and can be dependent on 
particle coating and cell type (Huth et al 2004; Berry et al 2006).
In this review we will focus primarily on the nanoparticles which are used for 
drug and gene delivery. In addition, applications and results of in vitro, animal and 
clinical experiments will be discussed. The theory and physical principles of magnetic 
nanoparticle-based drug and gene targeting have been reviewed elsewhere (Pankhurst 
et al 2003; Grief and Richardson 2005; Dobson 2006a, 2006b, 2006c).
Design and synthesis of magnetic nanoparticles
In biotechnology, the essential features of nanoparticles are their nano-scale dimensions, 
their magnetic properties and their capability of carrying active biomolecules for speciﬁ  c International Journal of Nanomedicine 2008:3(2) 170
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tasks (Moghimi et al 2001). In order to be easily localized/
targeted inside the human body, the nano-scale dimensions 
of particles allow them not only to pass through the narrow-
est blood vessels but also penetrate through cell membranes 
when necessary (Willard et al 2004). If these particles are fer-
romagnetic/superparamagnetic, they can be manipulated by 
an external magnetic ﬁ  eld, which can drive them to the target 
organs for gene (Plank et al 2003) or drug delivery (Lazaro et al 
2005). The active biomolecules bound to the surface of these 
nanoparticles can then be released. As a result, a functional 
magnetic nanoparticle consists of a number of components; 
the magnetic core, the protective coating, and the surface 
functionality. For biomedical applications, magnetic nanopar-
ticles should also have active biomolecules according to the 
speciﬁ  c applications. Figure 1 shows a schematic design of a 
functional magnetic nanoparticle for biomedical applications. 
Other entities may also be included for multifunctional particles 
such as hybrid ﬂ  uorescent/magnetic particles. The challenge 
in this area is to put all these components together in a small, 
nanometer-scale space.
Synthesis of magnetic nanoparticles
Many different synthetic routes of magnetic nanoparticle 
synthesis have been reported (Li et al 2006). Some of them 
are one-step, while others are multi-step procedures. They 
all have advantages and disadvantages, and none of them 
provides a universal solution for all types of magnetic 
nanoparticles. One has to consider whether the chosen route 
is suitable for preparing a speciﬁ  c magnetic nanoparticles in 
a given environment with available instruments and facilities. 
Most of these procedures involve simple, basic inorganic 
chemistry, particularly iron chemistry. The following are 
several commonly used methods.
Wet precipitation and co-precipitation
Wet precipitation is one of the oldest methods for preparation 
of magnetic nanoparticles. By carefully controlling the pH 
of a iron salt solution, iron oxide forms as a ﬁ  ne suspension 
with particle sizes as small as 5 nm (Liu et al 2004). This 
simple method for making magnetic nanoparticles does not 
required any specialized facilities. Indeed, precipitation of 
the iron oxides is a simple, classic chemical testing method 
(qualitative analysis) for identifying the existence of iron(II) 
or iron(III) ions in an aqueous solution (Vogel 2000).
Mixed oxide particles (eg, magnetite Fe3O4, ferrites 
including CoFe2O4 NiFe2O4) can also be prepared by co-
precipitation with a stoichiometric solution of the two metal 
ions. For example, magnetite can be prepared by adding 
base to a mixture of Fe2+ and Fe3+ solution following the 
equation:
Fe2+ (aq.) + Fe3+ (aq.) + 8OH− (aq.)
  → Fe3O4 (s)+ 4H2O (l) 
(1)
However, preparation of mixed oxides via the co-precipitation 
method is less straightforward, as these metals precipitate at 
different pH values (Pourbaix 1974).
Unfortunately, there are also some drawbacks with this 
procedure. Controlling the pH is vital in order to control the 
particle size, which is governed by kinetic factors (LaMer 
and Dinegar 1950; Lagally 1993). Nanoparticles with broad 
particle size distributions and irregular morphologies are usu-
ally produced by wet precipitation. Oxidation of the iron(II) 
precursor also must be avoided for successful synthesis of 
magnetite. Since a large quantity of water is involved dur-
ing synthesis, scaling up is possible but not easy. Finally, 
since controlling the pH is delicate, it is virtually impossible 
to simultaneously precipitate a protective coating. After 
Figure 1 A typical design of a magnetic nanoparticle for biotechnology.International Journal of Nanomedicine 2008:3(2) 171
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preparation, coating these nanoparticles individually, without 
aggregation can be difﬁ  cult.
Reverse micelle mechanism
The formation of micelles is a classic phenomenon of surfac-
tant chemistry (Meyers 2005). Surfactants are molecules with 
a hydrophilic head and a long, hydrophobic tail (Figure 2). 
The formation of micelles occurs when the concentration 
of surfactant molecules reaches a certain level, or critical 
micelle concentration 1 (CMC1, while CMC2 is the concen-
tration triggering the self-assembly of liquid crystals which 
is not discussed here). Normal micelles form in an aqueous 
medium (such as using detergents in cleaning processes) but 
reverse micelles form in an oily medium (eg, hexane). The 
center of these reverse micelles is hydrophilic and stores 
the inorganic components of the reaction mixture. For the 
synthesis of iron oxide-based magnetic nanoparticles, inor-
ganic precursors such as iron(III) chloride are dissolved in 
an aqueous medium and added to the oily reaction mixture 
with the surfactants. This is followed by the addition of pH 
regulators (eg, ammonia or NaOH) and inorganic coating 
materials (eg, silica or gold).
With the help of micelles, the size of the particles can be 
easily controlled and consequently nanoparticles prepared 
using reverse micelle routes tend to be very homogeneous 
in size. Also, the inorganic coating materials can be added to 
the micelles during synthesis, so nanoparticles produced by 
this method can be coated with an inorganic protective layer 
during the process. Magnetite nanoparticles with inorganic 
coatings such as silica have been prepared using this method 
(Santra et al 2001). The size of these nanoparticles is at the 
range of a few nanometers to tens, or hundreds, of nanometers 
with a narrow distribution.
One drawback of this technique, however, is that syn-
thetic organic coatings are not possible as the monomers 
will remain in the organic phase of the micelle solution (ie, 
outside the micelles). The size of the nanoparticles is entirely 
dependent on the micelle size, which normally have a range 
of 20–500 nm. Synthesis of particles outside this range are 
not possible using the reverse micelle method. Finally, with 
such a large amount of organic solvent involved in making the 
micelles, the reverse micelle method is difﬁ  cult to scale-up.
Chemical vapor condensation (CVC)
When some volatile metal compounds are heated in a inert 
gas atmosphere, these compounds decompose and form 
metal nanoparticles. This method is termed chemical vapor 
condensation (CVC). Metallic iron nanoparticles prepared 
using CVC mechanism have been reported (Choi et al 
2001). In this work, iron carbonyl, Fe(CO)5, was used as 
iron precursor and the particle size averaged to 5–13 nm. 
Further oxidation of these metallic iron nanoparticles is 
possible. Magnetite nanoparticles of 3 to 20 nm (Sun and 
Zeng 2002) and maghemite nanoparticles of 4 to 16 nm 
(Hyeon et al 2001) were prepared by oxidation of metallic 
iron nanoparticles.
Although this technique produces high-quality nanopar-
ticles specialized facilities are required. More importantly, 
Figure 2 Illustration explaining the use of the reverse micelle mechanism in synthesizing magnetic nanoparticles.International Journal of Nanomedicine 2008:3(2) 172
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some of the precursors such as Fe(CO)5 are highly toxic (with 
CO as by-product) and difﬁ  cult to handle.
Thermal decomposition and reduction
When metal oxy-salts (such as nitrates, carbonates and ace-
tates) are heated to a certain temperature, they decompose to 
form metal oxides. For example, iron(III) nitrate decomposes 
to iron(III) oxide according to the following equation:
4Fe(NO3)3 (s) → 2Fe2O3 (s) + 12NO2 (g) + 3O2 (g)  (2)
These metal oxide nanoparticles can be further reduced to 
metal by heating the oxides to a certain temperature under 
a reducing gas, usually hydrogen (H2) or carbon monoxide 
(CO), following the equations:
  MO + H2 → M + H2O (3)
  MO + CO → M + CO2 (4)
This reduction method applies to most metal oxides except 
those of alkaline and alkaline earth metals (Nurmi et al 
2005).
With only very little solvent involved, this thermal 
method is popular with industry. However, control of 
the particle size is difﬁ  cult and the same problems as wet 
precipitation for particle coating hampers its use in some 
laboratories.
Liquid phase reduction
Liquid phase reduction usually is applied to reduce 
magnetic or non-magnetic metal oxides to magnetic metal or 
metal alloy, with the use of powerful reducing agents, such as 
NaBH4 and LiAlH4. NaBH4 is a particularly popular reducing 
agent in this area because it is soluble in both methanol and 
water. The reduction of metal oxides using NaBH4 follows 
the equations in Table 1 (Morris et al 1985).
The mechanism of reduction using NaBH4 can be com-
plicated. Details of reduction for Fe, Co, Ni are available in 
the literature (Klabunde 1996). Magnetic alloy nanoparticles 
can also be formed using liquid phase reduction of mixed 
metal salts or oxides (Srivastava et al 2006).
Although most hydrides are moisture sensitive and dif-
ﬁ  cult to handle, liquid phase reduction has some advantages 
over other synthetic methods. These hydrides are strong 
reactants so only mild conditions with standard laboratory 
facilities are required. Hydrides are also penetrative to 
some coatings, especially natural polymers so the particles 
can still be reduced even with “protective” coatings. How-
ever, some protective coatings may also be reduced by the 
hydride, including polyvinyl alcohol, polysaccharides and 
proteins.
Magnetic core material
There are many magnetic materials available with a wide 
range of magnetic properties. However, many of these 
materials, such as cobalt and chromium, are highly toxic 
and unlikely to be used as biomedical agents in vivo with-
out a non-toxic, protective coating with high mechanical 
strength. Iron oxide-based materials such as magnetite and 
maghemite, however, are relatively safe and are currently 
in use in the clinic as MRI contrast agents. The following 
are some magnetic materials suitable for use in biomedical 
applications. For a detailed review of their magnetic proper-
ties see Dobson (2007).
Magnetite Fe3O4
Magnetite is a common mineral which exhibits ferro 
(ferri)magnetic properties. Descriptions of the physical prop-
erties of magnetite are widely available (http://www.mindat.
org/min-2538.html). The structure of magnetite belongs to the 
spinel group, which has a formula of AB2O4. Its ferromagnetic 
structures arise from alternating lattices of Fe(II) and Fe(III). 
This gives it a very strong magnetization compared to naturally 
occurring antiferromagnetic compounds such as the ferrihydrite 
core of the ferritin protein.
Maghemite γ-Fe2O3
Maghemite, a topotactic oxidation product of magnetite, has 
the same lattice structure as magnetite but all iron atoms are in 
Fe(III) oxidation state. It can be thermally transformed to other 
forms of iron(III) oxides such as heamitite, which is antiferro-
magnetic. The strong magnetization of maghemite (about 100 
times stronger than hematite and ferrihydrite), which is on the 
order of magnetite, is due to lattice vacancies which give rise 
to uncompensated electron spins within the structure.
Maghemite is one of the most suitable materials for the core 
of magnetic nanoparticles because it is least likely to cause any 
health hazard. Iron (III) ions are widely found in human body 
so leaching of metal should not cause signiﬁ  cant side-effects. 
As a result, maghemite is a popular choice for making magetic 
nanoparticles, especially for biomedical applications.
Table 1 Standard redox potentials 
Chemical reaction  E°/V vs NHE at 25 °C
Fe2+ + 2e− → Fe  −0.440
BH4
− + 4OH− → BO2
− + 2H2O + 2H2 + 4e−  −1.73
N2H4 + 4OH− → N2 + 4H2O + 4e−  −1.16International Journal of Nanomedicine 2008:3(2) 173
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Iron-based metal oxides
There are many iron-based metal oxides which exhibit strong 
magnetic properties and can be used as magnetic cores for 
building the magnetic nanoparticles. Preparation procedures 
of mixed oxide nanoparticles such as CoFe2O4, NiFe2O4, 
MnFe2O4 are commonly found in the literature (Shaﬁ   et al 
1998). It is worth noting that these materials have a remark-
ably similar spinel structure to magnetite Fe3O4. However, 
using these mixed oxide nanoparticles in biomedical research 
can be hampered by the high toxicity of these transition 
metals (Co, Ni, Mn). Non-permeable coatings are needed to 
prevent leaching of these metals. Other common examples 
of mixed oxides involve alkaline earth metals such as barium 
(BaFe12O19) and strontium (SrFe12O19), which belong to the 
magnetoplumbite-system (Pankov 2004). Again, leaching of 
these alkaline earth metals can cause problems in biomedical 
applications.
Iron alloys
Although iron metal itself is a good material for magnetic 
applications, it is seldom used as core material for the syn-
thesis of magnetic nanoparticles unless they are coated with 
an inert, protective coating. Iron is exceptionally vulner-
able to corrosion in presence of water, ie, rusting. Robust, 
non-porous coatings are essential for nanoparticles with 
iron metal cores. Also, functionalizing the iron surface is 
not straightforward. Therefore, iron alloys, such as FePt 
and FeAu, are more popular as core materials for magnetic 
nanoparticles.
Other materials
Other possible core materials for magnetic nanoparticles include 
rare earth metal alloys and transition metal clusters. The use of 
these materials for magnetic nanoparticle core synthesis is still 
rare due to their potential toxic effects on the human body.
Coating materials
Nanoparticles are more reactive than bulk materials due 
to their high surface to volume ratio (Klabunde 1996). 
As a result, these magnetic core nanomaterials need to be 
protected against corrosion. This coating also prevents the 
leaching of potentially toxic components into the body dur-
ing in vivo applications. There are many choices of coating 
materials. One has to consider the nature of the coating 
and the ease of further functionalization to suit speciﬁ  c 
applications.
Natural polymers
Coating magnetic nanoparticles with natural polymers such as 
carbohydrates and proteins is common (Schroder et al 1986; 
Berry et al 2003; Nitin 2004; Ito et al 2005; de la Feuten and 
Penades 2006; Liang et al 2006; McDonald and Watkin 2006). 
Many natural polymers are biocompatible and therefore suit-
able for coating nanoparticles for biomedical applications. 
Table 2 shows some examples of magnetic nanoparticles with 
natural polymer coatings for biomedical applications.
Carbohydrates are particularly popular as coating materials 
for magnetic nanoparticles because of their biocompatibility. 
For example, dextran-coated magnetic nanoparticles have been 
Table 2 Properties of natural and synthetic polymers for coating magnetic nanoparticles
Polymer   Hydrophobicity   Applications   Reference 
Natural polymers
Carbohydrates:
  Dextran   Hydrophilic   Drug delivery   Yuan et al 2006 
    Radioimmunoassay   Li et al 1996 
    MR imaging   Morales et al 2003 
    Hyperthermia   Jordan et al 1999 
  Starch   Hydrophilic   Tumur targeting, MR imaging, x-ray imaging   Alexiou et al 2001 
Proteins:      
  Albumin   Hydrophilic   MR imaging   Roser et al 1998 
  RGD  Hydrophilic  Fluorescent imaging and MR imaging  Montet et al 2006
Lipids  Hydrophobic   Immunoassay   Matsunaga and Takeyama 1998 
Synthetic polymers     
Poly(ethyleneglycol) (PEG)   Hydrophilic   MR imaging   Kohler 2005
      Veiseh et al 2005
     Kohler  2005 
    Drug delivery   Gupta and Curtis 2004
Polyvinyl alcohol (PVA)   Hydrophilic   Drug delivery   Schulze et al 2005 
      Schulze et al 2006 International Journal of Nanomedicine 2008:3(2) 174
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used in many biomedical applications such as cancer treatment 
(Subramani 2006) and MRI (Chouly et al 1996), and they are 
commercially available. Functionalization is also possible by 
making use of the hydroxyl groups on the carbohydrate skeletons 
(Heinze et al 2006). In order to diversify the surface proper-
ties, dextran has also been used as a blend with other polymers 
(including chitosan, poly-L-latic acid, and silica) to form blended 
coatings for magnetic nanoparticles (Grüttner et al 2001).
Unfortunately, some of these natural polymer coating 
materials are water soluble and lack mechanical strength. 
Cross-linking is needed to prevent them from breaking down 
in water but they are still mechanically weak. Also, these 
coatings tend to be porous and sometimes show non-selective 
adsorption (Markovic 2006).
Synthetic organic polymers
Since many natural polymers lack mechanical strength while 
others, such as cellulose, are too rigid to be manipulated to coat 
nanoparticles, synthetic polymers may provide a solution to 
this problem. Synthetic polymers such as poly(ethyleneglycol) 
(PEG) (Nitin et al 2004), polyvinyl alcohol (PVA) (Godovsky 
1999; Qiu and Winnik 2000) and poly-L-lactic acid (PLA) 
(Mikhaylova 2004; Mertz et al 2005) are some examples or 
coatings for magnetic nanoparticles. The choice of synthetic 
polymer coating depends on the required surface properties 
for particular applications (Table 1).
One interesting example is PVA coating, which has the 
structure shown in Figure 3. The hydroxyl groups (-OH) on 
the polymer skeleton ensure the hydrophobic property of the 
coating, which resembles the surface chemistry of carbo-
hydrates such as dextran. The use of PVA-coated magnetic 
nanoparticles in biomedical applications has been reported 
(Schulze et al 2006). This research group has demonstrated 
the internalization of PVA and PVA co-polymer-coated 
magnetic nanoparticles by synoviocytes and by cells of the 
synovial membrane in sheep (Schulze et al 2005).
Although synthetic polymers have better mechanical 
strength than many natural polymers, some coatings formed 
Figure 3 The structure of PVA (a) which is compared with a polysaccharide (b) as both materials have abundant hydroxyl groups on surface. The crosslinking reaction is 
shown in (c). International Journal of Nanomedicine 2008:3(2) 175
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from synthetic polymers are still porous on molecular scales, 
which means that corrosion of the magnetic core is still possible. 
Also, some of these polymers are difﬁ  cult to further functional-
ize. For example, PEG is a polyether and has no apparent site for 
simple organic functionalization, except the end groups. Linking 
active biomolecules with organic linkers becomes difﬁ  cult.
Silica
Silica is an amorphous material with high mechanical strength. It 
carries negative charges at pH 3 because of the silanol groups 
(–Si–OH) on the surface. In order to alter the surface chemistry of 
silica, silylation can be carried out following scheme 1 with use 
of functional alkoxysilane, such as aminopropyltriethoxysilane, 
or ATPES (X = NH2 in Figure 4). Techniques for functionalizing 
silica surfaces for various biomedical applications are widely 
available in literature (Yiu et al 2001; Yiu and Wright 2005).
Coating silica on iron oxide particles can be difﬁ  cult as its 
amorphous structure prohibits silica from forming a homoge-
neous layer on the surface of the iron oxide. It normally results 
in the formation of silica spherical particles on the iron oxide 
surface with size comparable to the iron oxide nanoparticles. 
Hence, the overall particle size and shape are hard to control 
without structural directing agents such as surfactants (see section 
2.1.2) In general, silica coating is carried out as the hydrolysis of 
tetraethyl orthosilicate (TEOS, also known as tetraethoxysilane) 
at a certain pH (8–10) or the neutralization of silic acid.
Gold
Gold is one of the most commonly used materials for 
bioscience interfaces (Hu et al 2006; You et al 2006). 
It is not only very stable but also easily functionalized 
via thiol linkers (–SH) (Bertilsson and Leidberg 1993). 
Figure 5 shows how gold-coated magnetic nanoparticles 
can be functionalized with thiol linkers. It is well-known 
that thiols, and many other sulphur compounds, have 
high afﬁ  nity to the gold surface. Scientists have been 
exploiting this phenomenon in biotechnology, such as 
binding antigens for immunoassay (Ameur et al 2000; 
Susmel et al 2000).
Gold-coated magnetic nanoparticles were ﬁ  rst reported 
in 2001 when Lin et al (2001) prepared so-called “Fe@Au” 
(gold-coated iron) nanoparticles (18–80 nm in diameter) via 
the reverse micelle mechanism. The iron metal nanoparticles 
were prepared inside the micelle followed by gold coating. 
To avoid aggregation, 1-dodecanethiol (C12H25SH) was 
bound to the gold surface of the nanoparticles through a 
self-assembly mechanism. These gold-coated nanoparticles 
can be functionalized for binding biomolecules by using thiol 
linkers with a functional group (such as amine) at the other 
end of the molecules.
Organic linkers
Without surface modiﬁ  cation, biomolecules may not bind 
to the magnetic nanoparticles. Even if they do, the interac-
tion between biomolecules and the surface of nanoparticles 
can be very weak, resulting in the instant release of these 
molecules during the delivery with little control. As a result, 
surface modiﬁ  cation is necessary to create strong interactions 
to enhance the binding process of biomolecules and also to 
control the release mechanism.
Figure 4 Silylation of a silica surface using triethoxysilane.International Journal of Nanomedicine 2008:3(2) 176
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Modiﬁ  cation through organic linkers is commonly used, 
as organic linkers provide a wide range of surface properties 
to suit various biomolecules in many conditions. Common 
organic linkers are listed in Table 3. Among these organic 
linkers, those creating electrostatic interactions are the most 
popular as the binding force is relatively easy to manipulate, 
usually by the addition of ions or altering the pH of the media. 
In other cases, catalytic or redox reactions may be involved 
for the releasing process.
For the application of magnetic nanoparticles in gene 
and drug delivery, the most suitable surface is that which is 
strongly positively charged. For gene delivery, the nanopar-
ticles have to bind a large amount of negatively charged 
DNA molecules, ideally through electrostatic interactions, 
and release them after internalization of the nanoparticles 
into the cell (McBain et al 2007).
For drug delivery, although not all drugs are negatively 
charged, there are large numbers of common drugs that carry 
carboxylic acid groups in their molecular structure, such as 
ibuprofen and aspirin. These drugs are likely to bind strongly 
to nanoparticles with a positively charged surface. Once these 
drug-nanoparticle complexes reach the target organs, the drug 
molecules will be released in the presence of anions (such as 
chlorides and phosphates). In other cases, the binding strategy 
has to be considered individually.
It is worth noting that organic linkers can be built up on 
top of each other through organic reactions if necessary. For 
example, aldehyde is a commonly used functional surface 
for binding protein but it is usually built from reacting 
glutardialdehyde with a primary amine surface (Wong 
1993). However, it is advisable to keep the surface simple. 
If a multiple linker system is built on the nanoparticles, 
Figure 5 Illustration of the use of thiol linkers for binding biomolecules onto gold coated magnetic nanoparticles.
Table 3 Properties of organic linkers and their applications
Linkers   Formula   Property   Target biomolecules   Examples 
Amine   -NH2   Positively charged   Drugs   Ibuprofen Aspirin DNA 
 -NHR    -NH2 can form amide bond with – COOH  Proteins 
 -NR2      DNA molecules  
Carboxylic acid  -COOH   Negatively charged   Proteins   Lysozyme 
    Can form amide bond with –NH2     Antibodies 
    Can form ester bond with –OH    
Aldehyde   -CHO   Form imide bone with –NH2 Proteins    Enzymes 
Thiol   -SH   Form disulﬁ  de bridge  Proteins (with   Cytochrome c 
    (-S-S-) with other thiol groups or  cystine in structure)   Trypsin 
    cystine group     LipasesInternational Journal of Nanomedicine 2008:3(2) 177
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their size will be increased dramatically and thus reduce the 
efﬁ  ciency of delivery.
Magnetic nanoparticles
for gene delivery
Magnetic nanoparticles have been in clinical use for a number 
of years, primarily as contrast enhancement agents for mag-
netic resonance imaging (Pankhurst et al 2003). However, 
in order for magnetic particles to act as effective carriers for 
DNA or pharmaceutical agents, the surface of the particles 
must ﬁ  rst be modiﬁ  ed to enable attachment of the target 
molecules, as discussed above. Molecules may be attached to 
the surface of the particles in a number of ways, for example 
by employing cleavable linkers or alternatively by utilizing 
electrostatic interactions between the particle surface and the 
therapeutic agent. Alternatively, the target molecule(s) may 
be incorporated into a degradable outer shell which releases 
the molecule as the shell is broken down.
In the ﬁ  rst study to demonstrate targeted delivery of DNA 
using magnetic particles Cathryn Mah, Barry Byrne and col-
leagues (Mah et al 2000) at the University of Florida, coated 
adeno-associated virus (AAV) encoding Green Fluorescent 
Protein (GFP) to the surface of magnetic particles using a 
cleavable heparin sulfate linker. In this study, AAV2 conju-
gated to magnetic microspheres gave increased transduction 
efﬁ  ciency in both C12s cells cultured in vitro and in vivo 
following intramuscular injection to 129/svJ mice (Mah 
et al 2002).
Although the use of target speciﬁ  c linkers undoubt-
edly provides an elegant approach to the attachment of 
target molecules it is not always possible. An alternative 
approach for attaching DNA to the surface of particles 
is to employ the electrostatic interactions between the 
negatively charged phosphate backbone of DNA and posi-
tively charged molecules linked to the particle surface. A 
popular choice for this approach is the cationic polymer 
Polyethyleneimine (PEI). This was among the ﬁ  rst reported 
transfection agents and binds and condenses DNA due 
to the large number of secondary amine groups present 
along it’s chain length (Abdallah et al 1996). In addition, 
PEI facilitates lysosomal release of the complex following 
internalisation by buffering the intralysosomal pH causing 
the lysosome to rupture and release it’s contents (Akinc 
et al 2005). Since it is now understood that particle DNA 
complexes typically enter the cell by endocytosis through 
clatharin-dependent pits (Schillinger et al 2005), it is 
possible that this feature of PEI may remain beneﬁ  cial for 
PEI-coated particles.
Polyethyleneimine-coated magnetic particles were ﬁ  rst 
reported by Scherer et al in 2002 (Scherer et al 2002) and 
provided the ﬁ  rst example of in vitro magnetic nanoparticle-
mediated non-viral gene delivery. In addition to facilitat-
ing targeted gene delivery, the principle advantage of this 
approach is that the rapid sedimentation of the gene-particle 
complex onto the target area signiﬁ  cantly reduces both the 
time and dose of vector to achieve efﬁ  cient transfection. In 
their original study, Scherer et al demonstrated that asso-
ciation of DNA vectors with superparamagnetic nanopar-
ticles increased the transfection efﬁ  ciency of a number of 
commercial transfection reagents in vitro and enabled the 
duration of gene delivery to be reduced to as little as 10 
minutes. Furthermore, conjugation of adenoviral vectors to 
the particles enabled transduction of a number of cells lines 
that expressed little or no Coxsackie and adenovirus receptor 
(CAR). This ﬁ  nding provided further evidence to support the 
idea that associating viral vectors with nano- or microparticles 
may extend the host tropism to non-permissive cells. Since 
this original study, magnetofection has been used to transfect 
a number of cell types including primary lung epithelial cells 
(Gersting et al 2004) and blood vessel endothelial cells (Krotz, 
Sohn et al 2003). These particles have also been used to suc-
cessfully deliver antisense oligonucleotides (Krotz, de Wit et al 
2003), and small interfering RNA (siRNA) to downregulate 
gene expression. In a recent study by Schilinger et al (2005) 
siRNA associated with magnetic particles signiﬁ  cantly reduced 
retrovirally mediated expression of luciferase in Hela cells.
We have recently reported an alternative approach for 
synthesizing PEI coated magnetic particles based upon 
covalently coupling PEI to the surface of composite iron 
oxide, dextran silica particles using glutardialdehyde linkers. 
(McBain et al 2007)
To date, much of the work based upon linking DNA vec-
tors to magnetic particles has centered upon the ability of 
this approach to reduce the time needed for transfection, or 
minimize the dose of vector. Recent work by our group has 
focused on improving the overall transfection efﬁ  ciency of 
this technique by using dynamic magnetic ﬁ  elds produced 
from oscillating arrays of permanent rare earth magnets. 
Preliminary data from these studies suggest that this approach 
can improve the level of transfection 10 fold compared to 
static magnetic ﬁ  elds. We hypothesize that the oscillating 
ﬁ  elds introduce extra energy to the system which improves 
particle uptake. In addition, the non-linear motion of the 
particles as they move along the ﬁ  eld gradient may aid tissue 
penetration for in vivo applications and help overcome the 
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that exist in some clinical targets for gene delivery such as 
the CF lung.
Another novel, and interesting approach to nanoparticle 
mediated gene delivery has recently been reported by Cai 
et al (2005). Termed nanotube spearing, this approach 
is based upon using nickel embedded carbon nanotubes 
coated in DNA. When the nanotubes are introduced to cells 
in the presence of a speciﬁ  cally orientated magnetic ﬁ  eld, 
the nanotubes align with the magnetic ﬂ  ux lines as they are 
pulled towards the cells. This enables the nanotubes to spear 
the cells, pass through the membrane and deliver the target 
DNA, and has been successfully used to transfect a number 
of different cell types including Bal17 B-lymphoma, ex vivo 
B cells and primary neurons, whilst maintaining a high rate 
of cell viability after transduction.
Magnetic nanoparticles
for use in drug delivery
In essence, the idea of using magnetic micro- or nanoscale par-
ticles to target delivery of therapeutic agents can be traced back 
to the late 1970s. Work by Widder et al (1978, 1979) employed 
magnetically responsive micropsheres to deliver anti tumor 
drugs. Since these early studies, a number of other groups have 
demonstrated the efﬁ  cacy of this approach in numerous small 
animal studies (Alexiou 2000; Lubbe et al 2001).
Although magnetic targeting has been successful in a 
number of such studies, there remains only a small number 
of clinical trials to date. The ﬁ  rst Phase I clinical trial of 
magnetically targeted drug delivery was performed by 
Lubbe and co-workers in 1996 (Lubbe, Bergemann, Huhnt 
et al 1996; Lubbe, Bergemann, Riess et al 1996). In this 
study, epirubicine was complexed to nanoparticles on 
the basis of electrostatic interactions between phosphate 
groups bound to the surface of the particle and amino 
sugars present within the drug. The clinical study built 
upon previous work in mice and rats in which two forms of 
treatment were studied; mechanical occlusion of the tumor 
with high concentrations of ferroﬂ  uid and magnetically 
targeted delivery of epirubicin using lower concentra-
tions of particles. Interestingly, no LD50 could be found 
for the particle during these studies. In the clinical trial, 
of the 14 patients studied, epirubicin was effectively tar-
geted to the tumor site in 6 patients. As with many similar 
in vivo studies the particles not attracted to the site of the 
tumor accumulated in the liver but appeared to produce 
no abberent effects.
A second clinical trial was performed in 2002 by Koda 
et al (2002) on 32 patients with hepatocellular carcinoma. 
In this study, doxorubicin hydrochloride was coupled to 
a magnetic particle carrier and delivered by sub selective 
hepatic artery catheterization. The particle-drug complex was 
targeted to the tumor site using an external magnetic ﬁ  eld 
(500mT) and particle localization examined with MRI. Of the 
32 patients studied, tumors were targeted effectively in 30. 
At the time the article was published, analysis of 20 of these 
tumors in 17 patients showed that 15 tumors had remained 
stable or reduced in size and only 5 had progressed.
In a similar study, a third trial performed in 2004 exam-
ined the efﬁ  cacy of magnetic targeting for the treatment of 
four patients with hepatocellular carncinomas (Wilson et al 
2004). In this study, doxorubicin linked to magnetic carriers 
was delivered via the hepatic artery using concurrent mag-
netic resonance imaging. The particles were targeted to the 
tumor sites by using rare earth magnets placed on the body 
surface. The results suggested that the particle/drug complex 
was well focused to the tumor sites with between 64 and 91% 
of the tumor volume affected by the drug.
Conclusions
Though progress in clinical applications of magnetically 
targeted carriers has been slow since ﬁ  rst introduced in 
the 1970s, the potential for this technique remains great. 
Rapid developments in particle synthesis have enabled 
the use of new materials for more efﬁ  cient capture and 
targeting and novel strategies are being developed for 
applying magnetic ﬁ  elds which could lead to treatments 
for diseases such as cystic ﬁ  brosis and localized cancer-
ous tumors. Though clinical trials are few, the results have 
been promising. While magnetic targeting is not likely to 
be effective in all situations, with further development it 
should provide another tool for the effective treatment of 
a variety of diseases.
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